| Code | CSB-RA011050MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to mapalumab, targeting interferon gamma (IFNG), a critical cytokine central to immune regulation and host defense mechanisms. IFNG is primarily produced by T cells and natural killer cells, playing essential roles in activating macrophages, enhancing antigen presentation, and orchestrating both innate and adaptive immune responses. Dysregulated IFNG signaling is implicated in various pathological conditions including autoimmune diseases, inflammatory disorders, chronic infections, and certain malignancies, making it a significant target for immunological research.
Mapalumab, the reference antibody, is a fully humanizedized IgG1 monoclonal antibody that specifically neutralizes IFNG activity, preventing IFNG from activating immune cells, thereby suppressing a series of IFNG-driven inflammatory responses. This biosimilar provides researchers with a valuable tool for investigating IFNG-mediated pathways, studying cytokine networks in immune responses, and exploring therapeutic strategies for conditions characterized by excessive or aberrant interferon gamma production. The antibody is suitable for various in vitro and in vivo research applications aimed at understanding immune modulation and inflammatory processes.
There are currently no reviews for this product.